Search Results - "Ernstoff, M. S."

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group by Puzanov, I, Diab, A, Abdallah, K, Bingham, 3rd, C O, Brogdon, C, Dadu, R, Hamad, L, Kim, S, Lacouture, M E, LeBoeuf, N R, Lenihan, D, Onofrei, C, Shannon, V, Sharma, R, Silk, A W, Skondra, D, Suarez-Almazor, M E, Wang, Y, Wiley, K, Kaufman, H L, Ernstoff, M S

“…Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents…”
Get full text

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth by Titus, L.J., Clough-Gorr, K., Mackenzie, T.A., Perry, A., Spencer, S.K., Weiss, J., Abrahams-Gessel, S., Ernstoff, M.S.

“…Summary Background  Little is known about the potential benefit of skin self‐examination for melanoma prevention and early detection. Objectives  To determine…”
Get full text

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 by Kirkwood, J M, Strawderman, M H, Ernstoff, M S, Smith, T J, Borden, E C, Blum, R H

“…Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following…”
Get more information

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801 by KIRKWOOD, John M, IBRAHIM, Joseph G, SOSMAN, Jeffrey A, SONDAK, Vernon K, AGARWALA, Sanjiv S, ERNSTOFF, Marc S, RAO, Uma

“…Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant therapy for high-risk melanoma, are of interest because of…”
Get full text

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy by Haanen, J., Ernstoff, M.S., Wang, Y., Menzies, A.M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J.A., Obeid, M.

“…Patients with cancer and with preexisting active autoimmune diseases (ADs) have been excluded from immunotherapy clinical trials because of concerns for high…”
Get full text

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 by KIRKWOOD, J. M, IBRAHIM, J. G, SONDAK, V. K, RICHARDS, J, FLAHERTY, L. E, ERNSTOFF, M. S, SMITH, T. J, RAO, U, STEELE, M, BLUM, R. H

“…Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and…”
Get full text

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma by CHAPMAN, P. B, EINHORN, L. H, HOUGHTON, A. N, KIRKWOOD, J. M, MEYERS, M. L, SAXMAN, S, DESTRO, A. N, PANAGEAS, K. S, BEGG, C. B, AGARWALA, S. S, SCHUCHTER, L. M, ERNSTOFF, M. S

“…Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen) can induce major tumor…”
Get full text

Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient by Gastman, B.R., Ernstoff, M.S.

Get full text

Adjuvant Therapy of Stage III and IV Malignant Melanoma Using Granulocyte-Macrophage Colony-Stimulating Factor by SPITLER, L. E, GROSSBARD, M. L, ERNSTOFF, M. S, SILVER, G, JACOBS, M, HAYES, F. A, SENG JAW SOONG

“…To evaluate granulocyte-macrophage colony-stimulating factor (GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high risk of…”
Get full text

Homozygous Deletions within Human Chromosome Band 9p21 in Melanoma by Fountain, Jane W., Karayiorgou, Maria, Ernstoff, Marc S., Kirkwood, John M., Vlock, Daniel R., Titus-Ernstoff, Linda, Bouchard, Bridgitte, Vijayasaradhi, Setaluri, Houghton, Alan N., Lahti, Jill, Kidd, Vincent J., Housman, David E., Dracopoli, Nicholas C.

“…Genetic studies have implicated the early involvement of a gene on chromosome arm 9p in the development of cutaneous melanoma. We have performed…”
Get full text

Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma by MEEHAN, K. R, WU, J, BENGTSON, E, HILL, J, ELY, P, SZCZEPIORKOWSKI, Z, KENDALL, M, ERNSTOFF, M. S

“…A phase I/II trial evaluated early administration and dose escalation of interleukin (IL)-2 with granulocyte macrophage colony stimulating factor (GM-CSF)…”
Get full text

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide by Bennett, C L, Tosteson, T D, Schmitt, B, Weinberg, P D, Ernstoff, M S, Ross, S D

“…With the recent Southwest Oncology Group (SWOG) publication of their metastatic prostate cancer clinical trial results, which concluded that orchiectomy and…”
Get full text

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens by Givan, Alice L, Fisher, Jan L, Waugh, Mary, Ernstoff, Marc S, Wallace, Paul K

“…Fluorescent dyes that stain cell membranes or cytoplasm and then partition between daughter cells at division have been used in conjunction with flow cytometry…”
Get full text

Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens by Caubet, Jean-François, Tosteson, Tor D., Dong, Esther W., Naylon, Edward M., Whiting, Gregory W., Ernstoff, Marc S., Ross, Susan D.

“…To assess the survival benefit of maximum androgen blockade (MAB) using nonsteroidal antiandrogens (NSAAs) through meta-analysis of published randomized…”
Get full text

Tissue-shrinkage correction factor in the calculation of prostate cancer volume by SCHNED, A. R, WHEELER, K. J, HODOROWSKI, C. A, HEANEY, J. A, ERNSTOFF, M. S, AMDUR, R. J, HARRIS, R. D

“…Many studies that have calculated prostate cancer volumes from microscopic slides have used correction factors, ranging from 1.22 to 1.5, to compensate for…”
Get full text

In vivo description of dendritic cells in human renal cell carcinoma by Schwaab, T, Schned, A R, Heaney, J A, Cole, B F, Atzpodien, J, Wittke, F, Ernstoff, M S

“…Dendritic cells (DCs) are efficient and effective antigen-presenting cells that play a major role in initiating the primary immune response. They are the most…”
Get more information

Interferons in the treatment of human cancer by Kirkwood, J M, Ernstoff, M S

“…The interferons are the best known of biologic antineoplastic agents. Progress with the clinical application of interferons to cancer has been slow and…”
Get more information

Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma by CARDI, G, HEANEY, J. A, SCHNED, A. R, ERNSTOFF, M. S

“…The functional expression of Fas-ligand on tumor cells reported in a variety of neoplasms has been proposed by several groups as a mechanism of tumor escape…”
Get full text

Melanoma. Screening and education by Ernstoff, M S

“…Identification of early and thin cutaneous melanoma has a significant impact on overall survival. Through education efforts physicians, health care providers,…”
Get more information

Taxanes Synergize with the Bispecific Antibody MDXH447 to Enhance Antibody-Dependent Cell-Mediated Cytotoxicity by Tretter, C.P.G., Lewis, L.D., Fisher, J., Waugh, M.G., Ernstoff, M.S.

“…The interaction between antibody based therapy and cytotoxic chemotherapy is complex. To explore these interactions we investigated, in vitro, the effects of…”
Get full text